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Report
Mutations that Cause Osteoglophonic Dysplasia Define Novel Roles
for FGFR1 in Bone Elongation
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Shoji Ichikawa,2 Joanna Fields,1 Xijie Yu,1 Nick J. Shaw,4 Neil J. McLellan,4 Carole McKeown,5
David FitzPatrick,6 Kai Yu,7 David M. Ornitz,7 and Michael J. Econs1,2
Departments of 1Medical and Molecular Genetics and 2Medicine, Indiana University School of Medicine, Indianapolis; 3Department of
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Activating mutations in the genes for fibroblast growth factor receptors 1–3 (FGFR1–3) are responsible for a diverse
group of skeletal disorders. In general, mutations in FGFR1 and FGFR2 cause the majority of syndromes involving
craniosynostosis, whereas the dwarfing syndromes are largely associated with FGFR3 mutations. Osteoglophonic
dysplasia (OD) is a “crossover” disorder that has skeletal phenotypes associated with FGFR1, FGFR2, and FGFR3
mutations. Indeed, patients with OD present with craniosynostosis, prominent supraorbital ridge, and depressed
nasal bridge, as well as the rhizomelic dwarfism and nonossifying bone lesions that are characteristic of the disorder.
We demonstrate here that OD is caused by missense mutations in highly conserved residues comprising the ligand-
binding and transmembrane domains of FGFR1, thus defining novel roles for this receptor as a negative regulator
of long-bone growth.
The fibroblast growth factors (FGFs) and their receptors
(FGFR1–4) play key roles in skeletal development. The
FGFRs are part of the tyrosine kinase receptor family
and comprise an extracellular ligand-binding domain,
a single transmembrane domain, and an intracellular
tyrosine kinase region (Ruta et al. 1989; Ornitz and
Itoh 2001). Activating mutations in FGFR1–3 result in
skeletal disorders. FGFR1 and FGFR2 mutations cause
syndromes involving craniosynostosis, such as Pfieffer,
Crouzon, and Apert syndromes, whereas the dwarfing
syndromes, such as achondroplastic and hypochondro-
plastic dwarfism, are associated with FGFR3 mutations
(Muenke et al. 1994; Reardon et al. 1994; Shiang et al.
1994). Osteoglophonic dysplasia (OD [MIM 166250])
is an autosomal dominant disorder that shares charac-
teristics with both the craniosynostosis syndromes and
the dwarfing syndromes. OD is characterized by cranio-
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synostosis, prominent supraorbital ridge, and depressed
nasal bridge, as well as by rhizomelic dwarfism and non-
ossifying bone lesions. However, the genetic basis for
the unique skeletal phenotype associated with OD is
unknown.
A kindred with OD that consisted of a father and two
sons was recognized because of skeletal complications
and progressive weakness in the family members. The
proband (patient 1) and the affected father (patient 2)
were evaluated (fig. 1a). Patient 1 possessed a distinct
OD facial phenotype characterized by craniosynostosis,
severe nasal maxillary hypoplasia, telechanthus, and
prominent supraorbital ridge (fig. 1a). Patient 1 also had
growth retardation, with a peak stature of 40 in (101.6
cm) and a weight of 100 lb (45.36 kg). The proband’s
father and brother (fig. 1a) had the same skeletal syn-
drome (the father’s peak stature was 48 in [121.92 cm];
see fig. 1b). They also had shortened necks, broad and
shortened thumbs, brachydactyly, and generalized os-
teopenia. In addition, patients 1 and 2 never had tooth
eruption, as documented by radiographs.
The direct sequencing of all exons in FGFR1–4, as
well as the novel decoy receptor gene FGFR5, by use of
DNA samples from this family, revealed a heterozygous
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Figure 1 Kindred including patients 1 and 2 with OD. a, The proband (patient 1, shown here after multiple corrective surgeries). He
had severe craniofacial abnormalities, including craniosynostosis, telechanthus, and facial hypoplasia, as did his father (patient 2) and brother
(infant and adult photographs of the brother are shown). b, Patient 2; note reduced stature. c, The heterozygous 1115GrA (Y372C) missense
mutation in patients 1 and 2, as detected by DNA sequencing. This change was not found in normal controls or in the proband’s grandmother.
1115GrA missense mutation within exon 10 of FGFR1
(fig. 1c). This change replaces a tyrosine with a cys-
teine residue at amino acid position 372 (Y372C),
which maps to the extracellular juxtamembrane region
of FGFR1. Unaffected family members were negative for
the mutation, and no other nucleotide substitutions in
FGFR1 were found. In addition, this change disrupts an
RsaI restriction site and was not found in RFLPs from
880 control alleles (not shown). Tyrosine at position 372
is conserved among all FGFRs. The analogous muta-
tions that result in unpaired cysteine residues in FGFR2
(Y375C) and FGFR3 (Y373C) cause Beare-Stevenson
cutis gyrata syndrome (characterized by furrowed skin,
acanthosis nigricans, craniosynostosis, digital anoma-
lies, and early death [Hall et al. 1992; Przylepa et al.
1996]) and thanatophoric dwarfism type I (character-
ized by craniosynostosis, short ribs and bones of the
extremities, reduced vertebral bodies, and neonatal le-
thality [Rousseau et al. 1996]), respectively. It is inter-
esting that, although these mutations are analogous to
FGFR2 mutations that cause the skin disorders men-
tioned above, these patients do not have dermatologic
findings. Follow-up analysis of this kindred was not pos-
sible because the patients are deceased. Patient 1 died at
age 28 years, presumably from a pulmonary embolism
due to extended immobilization; patient 2 died at age
59 years, from respiratory distress under similar im-
mobilizing conditions; and the brother of patient 1 died
at age 24 years, from pneumonia.
An unrelated patient with OD (patient 3), was found
to have severe craniosynostosis, midface hypoplasia (fig.
2a), right choanal atresia, and mild rhizomelic short-
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Figure 2 Patient 3. a, Midface hypoplasia with low-set ears and telechanthus. b, Radiograph of the lower leg, revealing severe lesions at
the metaphases, as well as shortened bone length and decreased mineral density. c, The 929TrA (N330I) missense mutation of patient 3.
ening of the limbs, which became more pronounced with
further growth. In radiological analysis, severe femur
metaphyseal lesions were present (fig. 2b), and, similar
to the findings for patient 1, marked demineralization
of the long bones (fig. 2b), the mandible, and the maxilla
was observed. Patient 3 developed swelling that arose
from the lower gums, with a histologic appearance re-
sembling giant-cell granulomata. The swelling did not
respond to vinblastine or methotrexate, and, ultimately,
the growth of the lesions was suppressed by intravenous
bisphosphonate treatment.
The karyotype of patient 3 was normal, and DNA
analysis was negative for Pfeiffer syndrome mutations
and Muenke and Saethre-Chotzen syndromes muta-
tions—FGFR1 P252R and FGFR3 P250R, respectively
(Muenke et al. 1997; Paznekas et al. 1998). We then
identified a heterozygous TrA mutation (929TrA) in
exon 9 of FGFR1 (fig. 2c), which resulted in an aspar-
agine-to-isoleucine (N330I) mutation. This change cre-
ates a Tsp509I restriction site, which was not found in
200 control individuals by RFLP analysis (not shown).
Furthermore, the parents of patient 3 were negative for
the mutation, which indicates that it was a de novo DNA
mutation. N330 is a predicted glycosylation site, and
homologous mutations in FGFR2 (N331I) and FGFR3
(N328I) cause Crouzon syndrome (Steinberger et al.
1996) and hypochondroplasia (Winterpacht et al. 2000),
respectively. Of note, exon 9 includes the sequence en-
coding the C-terminal portion of D3, a domain that
plays a role in FGF binding and activation (Ornitz et al.
1996). Exon 9 is present only in the “c” isoform of
FGFR1, indicating that specific changes in FGFR1c will
lead to OD.
Similar to patients 1–3, patient 4 had clinical features
at age 2.5 years that were consistent with OD and in-
cluded prominent eyes, a short nose, palpable cranial
sutures, pansutural craniosynostosis (confirmed by ra-
diograph and CT scans; not shown), pectus excavatum,
and delayed tooth eruption (fig. 3a). Her head circum-
ference was in the 3rd percentile, and she had growth
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Figure 3 Patient 4. a, Craniosynostosis, midface hypoplasia, and telechanthus. b, Radiograph of the femur, showing lesions at metaphysis
(arrow). c, The 1135TrC (C379R) mutation of patient 4.
retardation (percentile !0.4) with bilateral flexion con-
tractures of her fingers. Furthermore, a skeletal survey
of patient 4 showed multiple lesions in the metaphyseal
regions of the long bones (fig. 3b), although they were
not as severe as those of patient 2.
In sequence analysis of FGFR1 in patient 4, a hetero-
zygous TrC mutation (1135TrC; C379R) was identi-
fied in exon 10 (fig. 3c), which resulted in a cysteine-
to-arginine change. This substitution interrupts an
HpyCH4V restriction site, and the change was not found
in 100 control individuals by RFLP analysis. Further-
more, both parents were negative for the mutation,
which indicates that it was a de novo substitution (not
shown). Cysteine at position 379 is predicted to reside
within the FGFR1 transmembrane domain, and muta-
tions in FGFR3 at the position homologous to C379
(G380R) are responsible for 190% of achondroplastic
dwarfism cases (Rousseau et al. 1994; Shiang et al. 1994;
Ikegawa et al. 1995).
In examination of the biochemistries of the patients
with OD, parallel observations were made in several
cases. Patient 1 and his father, patient 2, were hypo-
phosphatemic (1.0 mg/dl; normal, 2.7–4.5 mg/dl) sec-
ondary to renal phosphate wasting (tubular maximum
phosphate transport/glomerular filtration rates, 0.9 mg/
dl for patient 1 and 0.3 mg/dl for patient 2; normal,
2.5–4.5 mg/dl). This family also had 1,25-dihydroxy-
vitamin D concentrations that were inappropriately low,
given the degree of hypophosphatemia (10 pg/ml; nor-
mal, 25–45 pg/ml). In a similar manner, patient 3 became
hypophosphatemic (3.2 mg/dl; normal for children, 4.5–
5.5 mg/dl) at age 3 years as a result of isolated renal
phosphate wasting, with normal serum calcium, 25-hy-
droxyvitamin D, and alkaline phosphatase concentra-
tions. In this patient, parathyroid hormone (PTH) levels
fluctuated above the normal range, with unknown eti-
ology, early in life. Although PTH was suppressed during
the period of bisphosphonate treatment for lesions (aged
3–3.5 years), patient 3 remained hypophosphatemic. It
is interesting that isolated renal phosphate wasting has
not been a reported finding in OD. We previously de-
termined that a known phosphaturic factor, FGF23, is
produced by the nonossifying lesions in some patients
with fibrous dysplasia of bone and that elevated circu-
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Figure 4 Characteristics of OD mutations. a, Activation of FGFR1 and Y372C FGFR1 tested using cotransfection of wild-type FGFR1
and Y372C mutant FGFR1 with an FGFR1-responsive osteocalcin promoter-luciferase construct. Y372C FGFR1 had a 9-fold greater basal
activity, compared with that of wild-type FGFR1 ( ), and showed increased activity with FGF2 as ligand (20 pM, ; 200 pM,P ! .01 P ! .01
; 2,000 pM, ). b, Structure of FGFR1, with the relevant domains labeled. D1–3 p extracellular immunoglobulin-like domainsP ! .02 P ! .03
that comprise the FGF-binding domain; TM p transmembrane region; TK p tyrosine kinase domains 1–2. The thick bold line within D3
represents the known IIIb(exon 8)/IIIc(exon 9) splicing region. The positions of the OD mutations within FGFR1 exons 9 and 10 are indicated.
In the partial protein-sequence alignment of FGFR1-4 (bottom), the location of conserved residues with OD FGFR1 mutations are boxed, and
the transmembrane domains encoded by sequences within exon 10 are underlined.
lating concentrations of FGF23 are positively correlated
with phosphate wasting in these patients (Riminucci et
al. 2003). Similarly, the hypophosphatemia and dis-
turbed vitamin D metabolism observed in OD may be
caused by increased FGF23 production within the char-
acteristic radiolucent OD lesions (Beighton et al. 1980).
We therefore tested serum levels of FGF23 in patient 3,
which were indeed elevated (101 pg/ml; control mean
 SD, 30 20 pg/ml). Of note, patient 4 had normal
plasma phosphate concentrations and a normal serum
FGF23 concentration (32.6 pg/ml). Indeed, the lesional
burden is far greater in patient 3 than in patient 4 (figs.
2b and 3b), which is inversely correlated with the serum
phosphate concentrations in these patients (not shown).
Patients 1 and 2 are deceased; therefore, we were unable
to determine their serum FGF23 values. However, be-
cause this family, parallel to patient 3, had the char-
acteristic OD skeletal phenotype and renal phosphate
wasting, we would hypothesize that serum FGF23 was
elevated.
To determine whether the OD mutations were activat-
ing mutations, wild-type FGFR1c and Y372C FGFR1c
were assayed for ligand-independent and ligand-de-
pendent activity. The FGFR1 Y372C missense mutation
was introduced into the FGFR1 cDNA by use of a
nested-PCR site-directed mutagenesis approach (Yang et
al. 1994). Wild-type and mutant receptors were cotrans-
fected with an osteocalcin FGF response element pro-
moter-luciferase reporter into the osteogenic MC3T3 cell
line (Newberry et al. 1996). In the absence of exogenous
FGF, the basal activity of Y372C FGFR1 was elevated
9-fold, as compared with that of wild-type FGFR1
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( ), which indicates that the mutation causes li-P ! .01
gand-independent activation of FGFR1 (fig. 4a). Both
wild-type and Y372C FGFR1 responded to increasing
concentrations of FGF2, a known ligand for FGFR1c
(Ornitz et al. 1996). At all concentrations tested, FGF2-
mediated activity was significantly higher for the Y372C
FGFR1 mutant compared with the wild type (fig. 4a).
In summary, OD is caused by activating mutations in
highly conserved residues of FGFR1, within a limited
region comprising the D3 domain, a linker region, and
the initial transmembrane domain. Previously charac-
terized mutations in FGFR1–3-associated skeletal dys-
plasias lead to inappropriate receptor signaling through
covalent and noncovalent receptor dimerization and ac-
tivation (Neilson and Friesel 1996; Li et al. 1997), in-
creased ligand-binding affinity (Anderson et al. 1998;
Ibrahimi et al. 2001), altered specificity for FGF binding
(Yu et al. 2000), and direct activation of the FGFR ty-
rosine kinase domains (Neilson and Friesel 1996). In
contrast, inactivating mutations in FGFR1 are respon-
sible for autosomal dominant Kallmann syndrome, char-
acterized by hypogonadism and anosmia (Dod et al.
2003); thus, it is highly likely that the OD N330I and
C379R mutations, in addition to the Y372C substitu-
tion, are gain-of-function mutations. It is thought that
activation of FGFR3 is responsible for negative regu-
lation of bone elongation, because Fgfr3 null mice have
increased long-bone length (Deng et al. 1996) and be-
cause of the relatively common occurrence of activating
mutations in FGFR3-related achondroplasia (Naski et
al. 1996). The most common FGFR1-activating muta-
tion (P252R) causes the craniosynostosis disorder Pfeif-
fer syndrome (Muenke et al. 1994); thus, FGFR1 has
been associated primarily with flat bone growth and
skull formation. Because the Fgfr1 null mouse is neo-
natal lethal (Deng et al. 1994) and because of the rarity
of OD, the role of FGFR1 in long-bone growth has not
been fully recognized. In long bones, FGFR1 expression
is spatially separated from that of FGFR3, as the epi-
physeal growth plate is formed. Prehypertrophic and
hypertrophic chondrocytes, osteoblasts, and perichon-
drium express FGFR1, whereas FGFR3 is found in
proliferating chondrocytes and adult osteoblasts (Peters
et al. 1992; Deng et al. 1996; Delezoide et al. 1998;
Xiao et al. 2004). Together with the expression profile
of FGFR1 in bone, the exon 9 mutation (N330I) dem-
onstrates that the activation of the FGFR1c isoform has
profound effects on long bones, possibly by regulation
of skeletal formation through suppression of chondro-
cyte or osteoblast function. It is interesting that patients
1 and 2 had respiratory difficulties, which is not a typical
characteristic of other FGFR syndromes. The patients
did not have rib deformities; thus, there are two things
that most likely affected respiratory function. The hy-
pophosphatemia and marked reduction in calcitriol con-
centration may have led to weakness, which resulted in
poor inspiratory effort with atelectasis, thereby predis-
posing the patients to pneumonia. In addition, it is like-
ly that immobilization led to a pulmonary embolus in
patient 1 and, possibly, in his father (patient 2) and/or
brother.
In summary, OD is a disorder that shares skeletal char-
acteristics with both the craniosynostoses and the dwarf-
ing syndromes. OD is caused by activating mutations in
FGFR1, which thus reveals novel critical functions of the
FGFR1 receptor in the modulation of bone elongation.
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